The stock of BioScrip Inc (NASDAQ:BIOS) is a huge mover today! About 406,031 shares traded hands. BioScrip Inc (NASDAQ:BIOS) has risen 37.13% since March 8, 2016 and is uptrending. It has outperformed by 27.81% the S&P500.
The move comes after 5 months negative chart setup for the $349.87M company. It was reported on Oct, 11 by Barchart.com. We have $2.64 PT which if reached, will make NASDAQ:BIOS worth $45.48 million less.
Analysts await BioScrip Inc (NASDAQ:BIOS) to report earnings on November, 2. They expect $-0.06 EPS, up 68.42% or $0.13 from last year’s $-0.19 per share. After $-0.08 actual EPS reported by BioScrip Inc for the previous quarter, Wall Street now forecasts -25.00% EPS growth.
BioScrip Inc (NASDAQ:BIOS) Ratings Coverage
Out of 2 analysts covering BioScrip (NASDAQ:BIOS), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. BioScrip has been the topic of 2 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The rating was maintained by Dougherty & Company with “Buy” on Wednesday, August 12. As per Tuesday, August 11, the company rating was downgraded by SunTrust.
According to Zacks Investment Research, “BioScrip provides comprehensive pharmaceutical care solutions. We partner with healthcare payors, pharmaceutical manufacturers, government agencies, physicians, and patients to deliver cost effective programs that enhance the quality of patient life. We focus our products and services in two core areas: specialty medication distribution and clinical management services, both nationally and community-based and pharmacy benefit management services.”
Insitutional Activity: The institutional sentiment increased to 1.51 in 2016 Q2. Its up 0.36, from 1.15 in 2016Q1. The ratio increased, as 13 funds sold all BioScrip Inc shares owned while 26 reduced positions. 24 funds bought stakes while 35 increased positions. They now own 92.45 million shares or 63.22% more from 56.64 million shares in 2016Q1.
Camber Mngmt Ltd Liability Com accumulated 10.18 million shares or 1.25% of the stock. Oxford Asset Mgmt accumulated 68,877 shares or 0.01% of the stock. Tudor Corporation Et Al accumulated 0.01% or 247,500 shares. Amalgamated National Bank & Trust has 0% invested in the company for 10,820 shares. Moreover, Voya Management Ltd has 0% invested in BioScrip Inc (NASDAQ:BIOS) for 35,932 shares. Eidelman Virant has 0.66% invested in the company for 42,000 shares. Northern last reported 830,234 shares in the company. Bluemountain Capital Mgmt Limited Com reported 1.18M shares or 0.07% of all its holdings. The Texas-based Bridgeway Cap has invested 0.01% in BioScrip Inc (NASDAQ:BIOS). D E Shaw holds 1.02M shares or 0% of its portfolio. Wells Fargo And Mn has invested 0% of its portfolio in BioScrip Inc (NASDAQ:BIOS). Moreover, Oppenheimer & Company has 0% invested in BioScrip Inc (NASDAQ:BIOS) for 15,000 shares. Goldman Sachs Group has 0% invested in the company for 318,147 shares. Iguana Health Ltd Limited Liability Company accumulated 750,000 shares or 0.78% of the stock. Ardsley Advisory Prtnrs last reported 5.42M shares in the company.
More news for BioScrip Inc (NASDAQ:BIOS) were recently published by: Globenewswire.com, which released: “BioScrip Announces Transformative Acquisition of Home Solutions That Will …” on June 13, 2016. Moodys.com‘s article titled: “Moody’s downgrades BioScrip’s CFR to Caa2; outlook stable” and published on March 03, 2016 is yet another important article.
BIOS Company Profile
BioScrip, Inc., incorporated on March 22, 1996, is engaged in providing infusion solutions. The Firm partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Firm operates through Infusion Services segment. The Firm operates through approximately 70 service locations in over 30 states. The Firm offers home infusion services to provide clinical management services and the delivery of prescription medications.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.